Can a new injection calm psoriatic arthritis?

NCT ID NCT06640257

Ongoing Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests whether an investigational drug called SHR-1314 can reduce joint pain, swelling, and skin symptoms in adults with active psoriatic arthritis. Participants receive either SHR-1314 or a placebo injection over 24 weeks, with follow-up for safety. The study aims to see if more people achieve a 20% improvement in arthritis symptoms compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1314 injection
What this could lead to: If successful, SHR-1314 could offer a new treatment option to reduce joint pain, swelling, and skin plaques in people with psoriatic arthritis.
What could go wrong: This is a phase III trial, but results are not yet known. The drug may not prove more effective than placebo, and like other biologics, it could carry risks such as infections or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIATIC ARTHRITIS

Contacts and locations

Locations

Huashan Hospital of the Shanghai FuDan University

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.